ArticleFrontiers in oncology2026
A case report on the diagnosis and treatment of a glioneuronal tumor with ATRX alteration, kinase fusion, and anaplastic features.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioneuronal tumor with ATRX alteration, kinase fusion, and anaplastic features (GTAKA) is a rare pathological subtype of the central nervous system, with currently limited research available. This case report details a 37-year-old woman who developed a new intracranial tumor 22 years after initial treatment (surgical resection and adjuvant radiotherapy) for a WHO grade 2 astrocytoma. The new lesion was histopathologically diagnosed as GTAKA, a distinct glioneuronal tumor entity, following which the patient received adjuvant radiotherapy with concomitant temozolomide chemotherapy. Although this pathological type is rare, the immunohistochemical and molecular findings, combined with the therapeutic approach in this case, contribute to a deeper understanding of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.